Search hospitals > Alaska > Anchorage
Katmai Oncology Group
Claim this profileAnchorage, Alaska 99508
Global Leader in Thyroid Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Stomach Cancer
Conducts research for Breast cancer
217 reported clinical trials
6 medical researchers
Summary
Katmai Oncology Group is a medical facility located in Anchorage, Alaska. This center is recognized for care of Thyroid Cancer, Breast Cancer, Lung Cancer, Stomach Cancer, Breast cancer and other specialties. Katmai Oncology Group is involved with conducting 217 clinical trials across 447 conditions. There are 6 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Nitya Alluri, and Krishna C. Alluri.Area of expertise
1Thyroid Cancer
Global LeaderStage IV
Stage III
Stage I
2Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
Top PIs
Alison K. ConlinProvidence Portland Medical Center6 years of reported clinical research
Expert in Thyroid Cancer
Expert in Breast Cancer
107 reported clinical trials
183 drugs studied
Charles W. DrescherProvidence Portland Medical Center8 years of reported clinical research
Expert in Thyroid Cancer
Studies Uterine Tumors
53 reported clinical trials
99 drugs studied
Nitya AlluriProvidence Portland Medical Center1 year of reported clinical research
Expert in Thyroid Cancer
Studies Relapse
28 reported clinical trials
79 drugs studied
Krishna C. AlluriProvidence Portland Medical Center5 years of reported clinical research
Expert in Thyroid Cancer
Studies Stomach Cancer
26 reported clinical trials
63 drugs studied
Clinical Trials running at Katmai Oncology Group
Breast Cancer
Lung Cancer
Bladder Cancer
Non-Small Cell Lung Cancer
Pancreatic Cancer
Breast cancer
Ovarian Cancer
Multiple Myeloma
Bladder Carcinoma
Stomach Cancer
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Low Dose Tamoxifen
for Breast Cancer
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.
Recruiting2 awards Phase 38 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Katmai Oncology Group?
Katmai Oncology Group is a medical facility located in Anchorage, Alaska. This center is recognized for care of Thyroid Cancer, Breast Cancer, Lung Cancer, Stomach Cancer, Breast cancer and other specialties. Katmai Oncology Group is involved with conducting 217 clinical trials across 447 conditions. There are 6 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Nitya Alluri, and Krishna C. Alluri.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.